Patents Represented by Attorney Hannah O. Green
  • Patent number: 5175165
    Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: December 29, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Todd A. Blumenkopf, Thomas Spector, Devron R. Averett, Robert W. Morrison, Jr., Eric C. Bigham, Virgil L. Styles
  • Patent number: 5166160
    Abstract: The present invention is concerned with the compound of formula (I) ##STR1## and its acid addition salts. The invention is also directed to the use of the compound of formula (I) and its pharmaceutically acceptable acid addition salts as positive conotropic agents in mammals.
    Type: Grant
    Filed: August 11, 1988
    Date of Patent: November 24, 1992
    Assignee: Burroughs Wellcome Co.
    Inventor: Arthur P. Phillips
  • Patent number: 5153318
    Abstract: The present invention relates to 3'-azido purine nucleosides and their use in medical therapy, particularly for the treatment of human immunodeficiency virus and hepatitis B virus infections, to methods for their preparation and to compositions containing them.
    Type: Grant
    Filed: October 2, 1990
    Date of Patent: October 6, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Janet L. Rideout, George A. Freeman, Steven A. Short, Merrick R. Almond, Jon L. Collins
  • Patent number: 5104870
    Abstract: Novel (2S, 3S, 5R) morpholinols of formula (I) ##STR1## together with the (+-)-(2R*,3R*,5S*) racemates thereof, and their salts, whereinX is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms or a group --CH.sub.2 --X.sup.1 where X.sup.1 is cycloalkyl of 3 to 6 carbon atoms.The compounds have a variety of uses in human medicine, in particular in the treatment of mental disorders such as depression.
    Type: Grant
    Filed: April 2, 1991
    Date of Patent: April 14, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: James L. Kelley, David L. Musso, Grady E. Boswell, Barrett R. Cooper
  • Patent number: 5104897
    Abstract: A class of halogen-substituted diphenylsulfide compounds are disclosed which produce a large selective inhibition of serotonin uptake in brain. Such compounds are useful in the treatment of depression, anxiety, obsessive compulsive disorders and substance abuse disorders such as alcoholism.
    Type: Grant
    Filed: June 28, 1991
    Date of Patent: April 14, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Lawrence E. Brieaddy, Claudia E. B. Hollingsworth, Barrett R. Cooper
  • Patent number: 5102914
    Abstract: The present invention is concerned with compounds of formula (I) ##STR1## wherein R.sub.1 is hydrogen;R.sub.2 is carbonyl; andR.sub.3 is hydroxy;and salts thereof, with processes for preparing same and with their use in medicine for the treatment of hypertension.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: April 7, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: John D. McDermed, Anjaneyulu S. Tadepalli, Vincent H. Chang, Kevin P. Hurley
  • Patent number: 5095039
    Abstract: A halogen-substituted diphenylsulfide compound is disclosed which produce a large selective inhibition of serotonin uptake in brain. This compound is useful in the treatment of depression as well as anxiety, obsessive compulsive disorders and alcoholism.
    Type: Grant
    Filed: June 5, 1990
    Date of Patent: March 10, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Nariman B. Mehta, Lawrence E. Brieaddy
  • Patent number: 5089500
    Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmceutical formulations and processes for the preparation of compounds according to the invention.
    Type: Grant
    Filed: May 8, 1991
    Date of Patent: February 18, 1992
    Assignee: Burroughs Wellcome Co.
    Inventor: Susan M. Daluge
  • Patent number: 5087697
    Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. The invention also relates to pharmaceutical formulations and processes for the preparation of compounds according to the invention.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: February 11, 1992
    Assignee: Burroughs Wellcome Co.
    Inventor: Susan M. Daluge
  • Patent number: 5071983
    Abstract: This invention relates to certain derivatives of 2', 3'-dideoxycytidine and their use in medical therapy particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the manufacture of the compounds according to the invention.
    Type: Grant
    Filed: October 6, 1989
    Date of Patent: December 10, 1991
    Assignee: Burroughs Wellcome Co.
    Inventors: George W. Koszalka, Thomas A. Krenitsky
  • Patent number: 5070078
    Abstract: 2',3'-Dideoxy-3'-fluoro pyrimidine nucleosides particularly 2',3'-dideoxy-3'-fluorothymidine have been found to have particularly potent activity against adenovirus infections especially those caused by adenoviruses of serotype 8. Such compounds are preferably presented in pharmaceutical formulations adapted for ophthalmic administration.
    Type: Grant
    Filed: August 19, 1988
    Date of Patent: December 3, 1991
    Assignee: Burroughs Wellcome Co.
    Inventors: John W. T. Selway, Lowrie M. Beacham, III, Susan M. Daluge, Joel Van Tuttle, Thomas A. Krenitsky
  • Patent number: 5068320
    Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and derivatives thereof. The compounds are useful as antivirals.
    Type: Grant
    Filed: October 6, 1989
    Date of Patent: November 26, 1991
    Assignee: Burroughs Wellcome Co.
    Inventors: George W. Koszalka, Charlene L. Burns, Thomas A. Krenitsky, Janet L. Rideout
  • Patent number: 5061708
    Abstract: The present invention relates to certain amino acid esters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment and prophylaxis of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.
    Type: Grant
    Filed: November 21, 1989
    Date of Patent: October 29, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Thomas A. Krenitsky
  • Patent number: 5049671
    Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
    Type: Grant
    Filed: December 22, 1989
    Date of Patent: September 17, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Susan M. Daluge
  • Patent number: 5049581
    Abstract: The present invention relates to compounds of formula(I) ArCh.sub.
    Type: Grant
    Filed: August 25, 1989
    Date of Patent: September 17, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Kenneth W. Bair
  • Patent number: 5043339
    Abstract: The present invention relates to amino acid esters of pyrimidine and purine nucleosides containing an acyclic side chain, and their use in medical therapy, particularly the treatment of herpes virus infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: August 27, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Lilia M. Beauchamp
  • Patent number: 5041543
    Abstract: A compound 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranoxyl)-5-methyl-2(1H)-pyr imidinone and its use in a method of generating (forming, providing) 3'-azido-3'-deoxythymidine (zidovudine sometimes referred to as AZT) in the body of an animal (a mammal such as human) by systemically administering 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl)-5-methyl-2(1H)-pyr iminone to said animal (mammal such as a human) is disclosed. AZT is approved and used for treating HIV infections, e.g., AIDS and ARC in humans and also has activity against gram-negative bacteria in animals.
    Type: Grant
    Filed: September 16, 1988
    Date of Patent: August 20, 1991
    Assignee: Burroughs Wellcome Co.
    Inventors: Sammy R. Shaver, George A. Freeman, Janet L. Rideout
  • Patent number: 5034394
    Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
    Type: Grant
    Filed: December 22, 1989
    Date of Patent: July 23, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Susan M. Daluge
  • Patent number: 5021437
    Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: June 4, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Todd A. Blumenkopf
  • Patent number: 5019577
    Abstract: The present invention provides a compound selected from:N-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-flurobenzoyl] -(L)-glutamic acid,N-[4-( 3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-flurobenzoyl ]-(L)-glutamic acid,N-[4 -(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-methylbenzoyl ]-(L)-glutamic acid,N-[4-( 2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-3-(methoxy)benzoy l](L)-glutamic acid andN-[4-(3 -(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propylamino)-2-chlorobenzoyl ](L)-glutamic acid,or a salt thereof, methods for the preparation of the compounds, intermediates in their preparations, pharmaceutical formulations containing them, and their use in the treatment of tumors.
    Type: Grant
    Filed: April 15, 1988
    Date of Patent: May 28, 1991
    Assignee: Burroughs Welcome Co.
    Inventor: Eric C. Bigham